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Abstract
Background/hypothesis HLA, INS, PTPN22 and CTLA4
are considered to be confirmed type 1 diabetes susceptibil-
ity genes. HLA, PTPN22 and CTLA4 are known to be
involved in immune regulation. Few studies have system-
atically investigated the joint effect of multiple genetic
variants. We evaluated joint effects of the four established
genes on the risk of childhood-onset type 1 diabetes.
Methods We genotyped 421 nuclear families, 1,331 patients
and 1,625 controls for polymorphisms of HLA-DRB1,
−DQA1 and −DQB1, the insulin gene (INS, −23 HphI),
CTLA4 (JO27_1) and PTPN22 (Arg620Trp).
Results The joint effect of HLA and PTPN22 on type 1
diabetes risk was significantly less than multiplicative in the
case-control data, but a multiplicative model could not be
rejected in the trio data. All other two-way gene–gene
interactions fitted multiplicative models. The high-risk
HLA genotype conferred a very high risk of type 1 diabetes
(OR 20.6, using the neutral-risk HLA genotype as
reference). When including also intermediate-risk HLA
genotypes together with risk genotypes at the three non-
HLA loci, the joint odds ratio was 61 (using non-risk
genotypes at all loci as reference).
Conclusion Most established susceptibility genes seem to
act approximately multiplicatively with other loci on the
risk of disease except for the joint effect of HLA and
PTPN22. The joint effect of multiple susceptibility loci
conferred a very high risk of type 1 diabetes, but applies to
a very small proportion of the general population. Using
multiple susceptibility genotypes compared with HLA
genotype alone seemed to influence the prediction of
disease only marginally.
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The risk of complex diseases such as type 1 diabetes is
generally thought to be influenced by multiple genetic and
non-genetic factors, and it has been hypothesised that
interactions between genes, or epistasis, are very common
for such diseases [1]. The presence of interactions could be
one of the reasons why searching for susceptibility loci for
many diseases has been less successful than expected [2].
When moving from monogenic diseases to complex
diseases, it seems reasonable to assess more than one locus
at a time, although models become increasingly complex as
the number of loci increases [3].
Whereas few or no common genetic variants have been
firmly established for most common diseases [4], there are
now at least four genetic loci that are established as causally
involved in the aetiology of type 1 diabetes. They give us a
unique possibility to evaluate gene–gene interactions
among established susceptibility genes. Specific allelic
combinations of DRB1, DQA1 and DQB1 in the human
leucocyte antigen (HLA) complex, variants in the insulin
gene (INS), the cytotoxic T lymphocyte antigen-4 gene
(CTLA4) and the protein tyrosine phosphatase, non-receptor
type 22 gene (PTPN22) have been repeatedly associated
with type 1 diabetes susceptibility [5–8] using different
approaches. All established loci are thought to be involved
somehow in immune regulation, but details of the mecha-
nisms relating the polymorphisms to risk of type 1 diabetes
are in most cases poorly understood.
Evaluating the joint effects of genes contributes impor-
tant information for risk prediction, and is also thought to
provide information about biological interactions, although
the latter is controversial and more complex than common-
ly thought [2, 3, 9].
Previous studies have assessed interaction between HLA
and INS and reported divergent results [10–18]. The reported
results of the joint effect of HLA and INS are confusing not
only because they have shown diverging results but also
because the definitions and terminology of interactions are
not consistent [19]. The interpretation of statistical interac-
tion depends on the choice of scale used to measure the
effects [2]. Although additivity of risks is often taken as
independence [20], multiplicativity of risk is sometimes also
taken as independence [21]. The joint action of HLA and
INS has variously been described as being multiplicative [14,
15], additive [13], providing evidence of interaction [15],
and non-interacting [13, 14, 17].
Few studies have investigated the more recently estab-
lished susceptibility loci PTPN22 and CTLA4 in the context
of joint effects on the risk of type 1 diabetes. The studies
that have been done have mainly concluded that there is a
non-interaction [22, 23] effect, but here also the results
have diverged [24–27].
The aim of our study was to assess the joint effects of the
four established susceptibility loci HLA, INS, CTLA4 and
PTPN22 in type 1 diabetes, using a consistent approach
with both population-based case-control and family trio
designs and with large sample sizes.
Methods
Participants We analysed two independent type 1 diabetes
data sets. One nuclear family set consisted of 421 trios with
mother, father and one child diagnosed in Norway with
type 1 diabetes before age 15 years (225 [53.4%] of the
affected children were boys). The families were collected
between 1993 and 1997. In families with more than one
affected sibling, only the proband was included in the
analyses. The case-control data set consisted of 1,331 type
1 diabetes patients (51.9% boys and 48.1% girls) and 1,625
(51.4% boys and 48.6% girls) control participants aged
<15 years. In analyses involving age of disease onset, we
divided the data sets according to age of disease onset of
the affected child into three groups (0–4.9, 5–9.9 and
≥10 years). The controls were randomly selected from the
official population registry among children born between
1985 and 1999 and recruited in 2001, as previously
described [28]. The patients in the case-control material
were from the Norwegian Childhood Diabetes Registry
consecutively recruited between 1997 and 2000 [29] and
between 2002 and 2005. The type 1 diabetes patients and
their family members were recruited by the Norwegian
Childhood Diabetes Study Group, including all paediatric
departments in Norway. All type 1 diabetes patients were
diagnosed according to EURODIAB criteria [30]. The
study was approved by the local ethics committee, and
informed consent was obtained from all participants or their
parents.
Genomic DNA extraction and genotyping In the majority of
the type 1 diabetes case-control samples we used DNA
extracted from buccal cells [31]. In all remaining samples,
DNA was extracted from peripheral whole blood using a
salting-out protocol. Genotyping of HLA-DRB1, −DQA1
and −DQB1 was performed using PCR-SSOP (sequence-
specific oligonucleotide probing) mainly following pub-
lished methods [32], or PCR-SSP (sequence-specific
primer) [33, 34], or using time-resolved fluorescence
technology in the Delfia assay (Perkin-Elmer Life Sciences,
Turku, Finland). HLA genotypes were grouped into four
risk categories based on DQB1, DQA1 and DRB1 geno-
types, including DRB1*04 subtyping. The majority of
DRB1*04-DQA1*0301-DQB1*0302 haplotypes in Norway
are DRB1*0401 or −0404 (constituting >94% of the
haplotypes) [35]. In the present study the other rare
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almost complete linkage disequilibrium between INS-VNTR
allele classes and the −23 HphI polymorphism, we geno-
typed −23 HphI (rs689) as a marker for the INS-VNTR. The
−23 HphI A allele corresponds to the VNTR class I and the
−23 HphI Ta l l e l ec o r r e s p o n dt ot h eVNTR class III. In
PTPN22 we genotyped the single nucleotide polymorphism
(SNP) Arg620Trp (rs2476601). The SNP JO27_1
(rs11571297) was genotyped in CTLA4. SNP genotyping
was performed by TaqMan allelic discrimination assays on
an ABI 7900HT DNA Analyzer (Applied Biosystems,
Foster City, CA USA). Primer and probe sequences are
shown in Electronic Supplementary Material (ESM) Table 1.
The PCR conditions are available on request.
Data analysis The HLA haplotypes were grouped as high
risk, intermediate risk, neutral risk and low risk according
to the following criteria: high-risk category, DRB1*0401/
04XX-DQA1*03-DQB1*0302/DRB1*03-DQA1*05-
DQB1*0201 (DR4-DQ8/DR3-DQ2); low-risk category, all
genotypes with at least one DQB1*0602 allele; intermedi-
ate-risk category, DRB1*0404-DQ8/DR3-DQ2, DR3-DQ2/
DR3-DQ2, DR4-DQ8/DR4-DQ8 (with the exception of
DRB1 0404-DQ8 homozygotes, which were grouped as
neutral), DRB1*0401 or 040XX-DQ8/X (X≠DQB1*0602 or
DR3-DQ2). The remaining haplotypes were grouped in the
neutral-risk category. For assessment of two-locus joint
effects, we pooled genotypes of INS, PTPN22 and CTLA4
as follows: INS class I/I genotypes were compared with I/III
together with III/III genotypes. The PTPN22 TT and CT
genotypes were compared with CC. CTLA4 (JO27_1)T T
genotypes were compared with TC and CC genotypes. Not
all individuals were genotyped for non-HLA polymor-
phisms because of lack of DNA. We did not exclude
individuals with some missing genotypes to prevent the
loss of important information when looking at joint effects
between polymorphisms. The available numbers of indi-
viduals for each analysis are seen in the tables. Data were
presented using stratified 2×2 tables and analysed using
logistic regression models including interaction (product)
terms, in SPSS for Windows (version 14.0; SPSS, Chicago,
IL, USA). In addition to formal analyses treating HLA
categories as categorical in the logistic regression, we also
tested for interactions when treating HLA category as a
continuous variable coded 1, 2, 3, 4, thus maximising the
power under alternative models where the effect of a non-
HLA locus (as measured by the odds ratio [OR]) was
assumed to decrease (or increase) (logit) linearly over the
four HLA risk categories (test for interaction with one
degree of freedom). Case-only analyses were used to
estimate interaction parameters and to test for deviation
from multiplicative effects using logistic regression [36]. In
addition to the increased power obtained by utilising all
cases (from case-control and trio materials) simultaneously,
case-only analyses have increased power by making the
implicit assumption that there is no association between the
two loci in the population; i.e. the OR for their association
is 1.0 in the population. Thus, under reasonable assump-
tions the case-only analysis makes the most efficient use of
data to assess deviation from multiplicative models. In the
case-control analysis, likelihood ratio tests comparing
nested logistic regression models were used as global tests
for interaction. The transmission disequilibrium test [37]
was performed using the UNPHASED application imple-
mented in the UNPHASED software version 2.4 [38]. For
the trio data, 95% confidence intervals for the relative risk
were estimated using conditional logistic regression in
UNPHASED. Receiver operating curve (ROC) and confi-
dence bounds for the area under the curve were estimated
assuming a non-parametric distribution and analyses were
done using SPSS version 14.0. Genotypes were added
sequentially in order of likelihood ratio (or equivalently by
the absolute risk conferred by a given genotype combination
estimated using Bayes’ formula). Two four-locus genotype
combinations were absent among cases in our material, and a
very low value for the estimated absolute risk was imputed
forthese toallowinclusionintheROC curve estimationwith
all four loci simultaneously. A p value <0.05 was considered
to be statistically significant.
Results
The single-locus main effects are shown in ESM Table 2
(case-control data) and ESM Table 3 (trios). Compared with
the neutral HLA risk category, the high-risk category
showed a strong association with type 1 diabetes, with
OR 20.6; for the intermediate-risk category the OR was 5.7
and for the low-risk category it was 0.09. INS, PTPN22 and
CTLA4 also showed an association with type 1 diabetes, as
expected. The transmission of the risk allele in the nuclear
families confirmed the associations in INS, PTPN22 and
CTLA4 (JO27_1), although with borderline significance for
JO27_1 (ESM Table 3).
Joint effect of HLA and PTPN22 ORs for the effect of
PTPN22 varied across the HLA risk categories and were
significant in some of the subgroups. The ORs were smaller
for the risk-conferring HLA genotypes, indicating negative
deviation from a multiplicative model. A global test of
interaction (with 3 df ) between HLA and PTPN22 in the
logistic regression model confirmed a significant interaction
(p=0.024). In the trio data, the relative risk conferred by the
PTPN22 T allele was similar in the strata defined by HLA
group, with no evidence for deviation from a multiplicative
model (ESM Table 4). A case-only analysis among all cases
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supported a significant negative deviation from multiplica-
tive effects, with weaker ORs conferred by PTPN22 in the
HLA risk categories (3 df test for interaction; p=0.028).
When treating HLA-encoded risk as a continuous variable
in the analysis (1 df ), the interaction was even more
statistically significant (p=0.003). There was no association
between HLA and PTPN22 among the controls (3 df test;
p=0.19). We tried to fit the case-control data to an additive
odds model using generalised linear models in STATA
(version 9), as described by Skrondal [39]. However,
convergence was not obtained, suggesting that the data
did not fit well to an additive model.
Joint effect of HLA and INS The 3 df test for interaction
between INS and HLA was not statistically significant (p=
0.67). There was also no statistically significant deviation
from a multiplicative model in the trio data (test for
interaction, p=0.5) (ESM Table 4) or in the case-only
analysis (3 df test; p=0.49) (ESM Table 5); even when
treating HLA-encoded risk as a continuous variable in the
analysis there was no significance (1 df test, p=0.12). There
was also no association between INS and HLA among
controls, as expected (3 df test; p=0.41).
Joint effect of HLA and CTLA4 The ORs for CTLA4 in the
different HLA categories (Table 1) indicated no deviation
Table 1 Interaction between HLA-INS (-23HphI), HLA-PTPN22 (Arg620Trp) and HLA-CTLA4 (JO27_1) in the case–control data set using
logistic regression
HLA category
a Non-HLA
genotypes
Cases Controls OR 95% CI Test for interaction
(p value) n (%) n (%)
INS
b 0.67
High risk I-I 218 (25.2) 20 (2.8) 1.56 0.76–3.21
III+ 98 (28.6) 14 (2.5) 1
Intermediate risk I-I 412 (47.6) 122 (17.1) 2.10 1.52–2.89
III+ 160 (46.8) 99 (17.4) 1
Neutral risk I-I 221 (25.5) 346 (48.5) 2.34 1.74–3.15
III+ 81 (23.7) 299 (52.6) 1
Low risk I-I 14 (1.6) 225 (31.6) 3.26 0.92–11.54
III+ 3 (0.9) 156 (27.5) 1
Total 1207 1281
PTPN22 0.024
High risk TT+TC 89 (23.2) 8 (3.1) 1.26 0.55–2.88
CC 237 (27.8) 27 (2.6) 1
Intermediate risk TT+TC 177 (46.1) 55 (21.2) 1.31 0.91–1.86
CC 406 (47.7) 164 (15.6) 1
Neutral risk TT+TC 111 (28.9) 121 (46.7) 2.44 1.80–3.31
CC 199 (23.4) 536 (51.0) 1
Low risk TT+TC 7 (1.8) 75 (29.0) 3.27 1.18–9.06
CC 9 (1.1) 323 (30.8) 1
Total 1235 1309
CTLA4 0.53
High risk TT 122 (24.9) 14 (3.6) 0.90 0.45–1.84
TC-CC 210 (27.9) 22 (2.5) 1
Intermediate risk TT 241 (49.2) 65 (16.5) 1.59 1.14–2.23
TC-CC 346 (46.0) 148 (16.7) 1
Neutral risk TT 121 (24.7) 212 (53.8) 1.34 1.01–1.77
TC-CC 187 (24.9) 439 (49.7) 1
Low risk TT 6 (1.2) 103 (26.1) 1.80 0.63–5.18
TC-CC 9 (1.2) 275 (31.1) 1
Total 1242 1278
n, Number of cases/controls
aHLA risk categories: high risk, DQA1*03-DQB1*0302/DQA1*05-DQB1*0201 (DQ8/DQ2), where DRB1≠0404; low risk, at least one
DQB1*0602 allele independent of genotype on the other allele; intermediate risk, DRB1*0404-DQ8/DR3-DQ2, DR3-DQ2/DR3-DQ2, DR4-DQ8/
DR4-DQ8 (excluding homozygous DRB1 0404), DRB1*0401 or 040x-DQ8/X (X≠DQB1*0602 or DR3). The remaining haplotypes were grouped
in the neutral risk category (see Methods)
bRepresents genotypes III/III and I/III
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This was also the case in the trio data set (ESM Table 4)
and was supported by the case-only analysis (ESM Table 5;
3 df test; p=0.57). Again, there was no association between
the two loci among controls (3 df test; p=0.21).
Joint effects of non-HLA loci There was also no indication
of deviation from multiplicative two-locus joint effects of
PTPN22-INS, INS-CTLA4 or PTPN22-CTLA4 in the case-
control data (Table 2) or in the case-only analysis (ESM
Table 5) (all p>0.39). For the trios, the test for interaction
between PTPN22 and CTLA4 showed p=0.046 (ESM
Table 6). Taken together with the analysis of the case-
control and the case-only data, this weighs against any
deviation from a multiplicative two-locus joint effect also
of CTLA4 and PTPN22.
Joint effects of more than two susceptibility loci We also
tested models with all three-way and four-way interactions
involving the four susceptibility loci using logistic regres-
sion (categorising all loci in two groups: increased risk
genotypes or not), but none of the multi-way interactions
were statistically significant (all p>0.29). The simultaneous
distribution of risk genotypes at all four loci among cases
and controls is shown in ESM Table 7. The results show
that the more risk loci an individual carries, the higher the
relative risk, but the presence or absence of HLA risk loci
influences the relative risk much more than the other loci,
as expected. For instance, carrying risk genotypes at all
three non-HLAloci butnotatHLAisassociated withamuch
lower risk than HLA risk genotypes together with low-risk
genotypes at all three other loci. The relative risk (OR)
conferred by simultaneously carrying high- or moderate-risk
HLA and risk genotypes at all the three other loci compared
with non-risk-associated genotypes at all four loci was 61.
The expected relative risk under a strict multiplicative model
involving all four loci was 123 (multiplying all four single-
locus effects by each other). The relatively small number of
individuals simultaneously carrying all risk genotypes
indicates that the observed negative deviation from a four-
way multiplicative model was not statistically significant, in
accordance with the formal test cited above.
ROC curve Another way to assess the predictive utility of
combinations of genetic risk markers is the ROC curve
[40]. This utilises the genotypes of all included individuals
and assesses the combination of sensitivity and specificity
of different combinations of genotypes. ROC curves for
HLA alone, pairwise combinations of HLA and non-HLA
loci, and multiple genotypes (Fig. 1) showed an area under
the curve of 0.82 for HLA alone, which was only
marginally increased by adding non-HLA loci.
Table 2 Interaction between INS-PTPN22, INS-CTLA4 and PTPN22-CTLA4 in the case-control data set using logistic regression
Non-HLA genotypes Cases Controls OR 95% CI Test for interaction
a
(p value)
n (%) n (%)
INS PTPN 0.67
I-I TT+TC 274 (72.9) 156 (58.4) 1.74 1.38–2.18
I-I CC 594 (71.6) 587 (54.8) 1
III+ TT+TC 102 (27.1) 111 (41.6) 1.89 1.38–2.58
III+ CC 236 (28.4) 485 (45.2) 1
Total (n) 1,206 1,339
INS CTLA4 0.42
I-I TT 354 (73.1) 222 (53.9) 1.51 1.23–1.86
I-I TC-CC 520 (71.0) 492 (54.8) 1
III+ TT 130 (26.9) 190 (46.1) 1.31 0.99–1.73
III+ TC-CC 212 (29.0) 405 (45.2) 1
Total (n) 1,216 1,309
PTPN CTLA4 0.78
TT+TC TT 143 (29.7) 75 (17.7) 1.46 1.04–2.05
TT+TC TC-CC 239 (31.7) 183 (20.1) 1
CC TT 339 (70.3) 348 (82.3) 1.4 1.15–1.67
CC TC-CC 514 (68.3) 729 (79.9) 1
Total (n) 1,235 1,335
The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)
aLikelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus
n, Number of cases/controls
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deviation from a multiplicative model concerning age–
locus and sex–locus interaction for any of the genes. This
was confirmed in the trio families and case-only analysis
(ESM Tables 8 and 9).
Discussion
The present study is a comprehensive evaluation of joint
effects of the four most well established type 1 diabetes
susceptibility genes in both a large case-control series and
family material. The relative risk conferred by PTPN22 was
stronger in the lower-risk HLA categories than in the high-
risk HLA category, while all other two-locus combinations
(HLA-INS, HLA-CTLA4, INS-CTLA4, INS-PTPN22 and
PTPN22-CTLA4) were consistent with multiplicative mod-
els. Although model-free methods have been developed for
gene–gene interaction studies, such as multifactor dimen-
sionality reduction (see [1] and references therein), these
methods are designed for the detection of novel suscepti-
bility loci, which was not the goal of our investigation.
Two of the three previous studies of the joint effect of
PTPN22 and HLA were in accordance with our results [25,
27] while the other study found no deviation from a
multiplicative model [22]. It should be noted that the
interaction between PTPN22 and HLA found in the case-
control material and case-only analysis was not replicated
in our trio data. One of the reasons for this could be lower
statistical power in the trio data. Using the Quanto program
([41]; http://hydra.usc.edu/gxe), we found that we had more
than 80% power to detect significant two-way gene–gene
interaction if the true interaction parameter was 0.5. For the
trio design we would need as many trios as we had cases in
the case-control study to obtain a similar power. Our
number of trios was only about a third of the number of
cases in the case-control study, with consequently lower
power. The case-only design is known to be the most
efficient to detect interaction under certain assumptions. For
instance, we had >99% power to detect interaction if the
true interaction parameter was 0.5.
The few studies concerning two-locus interaction effects
between HLA and CTLA4 and among non-HLA genes [22]
have generally indicated multiplicative effects, which is in
accordance with our results. Some previous studies have
found that the relative risk conferred by INS was similar in
subgroups defined by HLA susceptibility genes [11, 12],
while three studies have indicated that the effect was
stronger in the low risk-HLA categories [16–18], a finding
that was only partially supported by our data. On the other
hand, one relatively small study has found that the effect of
INS was confined to the high-risk HLA-DR4 group [10].
The reason for diverging results of the joint effect of
established type 1 diabetes susceptibility genes in the
literature could be that the studies have been performed
with varying sample sizes and with different study designs.
Linkage studies [14, 15], case-control association studies
[10, 12, 13, 16] and family trio designs [16, 18, 22, 25]
have all been used in these studies. Smaller studies might
be inadequate to reveal significant interactions. Different
criteria for categorising the HLA risk groups could
potentially influence the result of the joint effect of HLA
and other type 1 diabetes susceptibility genes. However,
our conclusions were not affected by alternative classi-
fication of HLA risk groups, such as into DR4-DQ8 vs
DR3-DQ2 carriers (data not shown). Studies in different
populations and ethnic groups have indicated some hetero-
geneity in HLA-associated risk of type 1 diabetes and it is
also possible that gene–gene interactions may vary across
populations. However, despite the observed variations in
population risk of type 1 diabetes and in HLA haplotype
frequencies across populations, the relative predisposing
effects of HLA haplotypes seem to be consistent across
populations [42]. In our study all the patients were
diagnosed before 15 years of age. The fact that the relative
risks associated with both risk genotypes and low-risk
genotypes seem to diminish with age above 15 years [43]
raises the question whether gene–gene interactions may
also differ in different age-groups.
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Fig. 1 ROC curve for HLA genotypes in four categories and for
combinations of genotypes defined by HLA and non-HLA suscepti-
bility loci. The area under the curve (95% confidence interval) was
0.820 (0.803–0.836) for HLA (dark blue line), 0.828 (0.811–0.844) for
HLA+CTLA4 (purple line), 0.835 (0.819–0.851) for HLA+PTPN22
(grey line), 0.840 (0.824–0.855) for HLA+INS (green line), 0.848
(0.833–0.863) for HLA+INS+PTPN22 (yellow line) and 0.852
(0.837–0.867) for HLA+INS+PTPN22+CTLA4 (red line). Turquoise
dashed line, reference line
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1 diabetes today, prediction of disease is an important part
of strategies for prevention, both for recruitment of
participants for research studies and for identification of
target populations for future preventive interventions.
Understanding the interacting effect of the established type
1 diabetes susceptibility genes will increase this possibility.
In a multiplicative model the relative risk (RR) for a person
holding a high-risk genotype at both loci compared with a
person with low risk at both loci will be RRlocus1×RRlocus2.
In terms of absolute risk differences, a doubling or tripling
of risk due to INS or PTPN22 would be greater for a person
with a high-risk HLA genotype than it would for someone
with a low-risk HLA genotype. The absolute risk for per-
sons with a given genotype can be estimated by multiplying
the average cumulative incidence in the population (0.42%
cumulative risk up to age 15 years in Norway [44]) by the
ratio of genotype frequency in patients and genotype
frequency in controls [18], or using Bayes’ formula. For
instance, for a person with a low-risk HLA genotype, a high-
or low-risk INS genotype will define whether the estimated
absolute risk is approximately 0.01% or 0.028% (absolute
risk difference, 0.027%), whereas for those with thehigh-risk
HLA genotype INS will define an estimated risk of
approximately 3.0% or 4.7% (absolute risk difference 1.7%).
As discussed in the general setting by Janssens et al.
[40], increasing the number of susceptibility loci considered
simultaneously generally increases the predictive value for
disease. The downside is that the proportion of the
population simultaneously carrying multiple risk alleles
becomes minute even with a moderate number of suscep-
tibility polymorphisms, and that even with relatively large
data sets, as in our study, the absolute risk estimate be-
comes imprecise. The high-risk HLA genotype is carried by
fewer than 3% of population controls, but confers a very
high risk of disease. Several practical and scientific aspects
of prediction should be considered when evaluating the
utility of different prediction regimes. The ROC curve
analysis confirms that, despite the higher absolute risk for
those few with combinations of several risk markers,
adding non-HLA genetic markers only marginally increases
the utility of the prediction over that of HLA alone. While
up to six susceptibility loci in addition to those studied here
have recently been established in type 1 diabetes [45], the
magnitude of the effect for each additional locus is very
much smaller than that of HLA and even smaller than that
of INS and PTPN22, suggesting that they are likely to add
only marginally to the prediction of disease in individuals.
Furthermore, an informal assessment of the number needed
to be genetically screened in order to obtain a cohort of
high-risk individuals, which will give rise to a given
number of cases of type 1 diabetes, and the costs connected
to the genotyping also suggest limited cost-effectiveness in
adding non-HLA genetic markers to the prediction regime
(data not shown).
In conclusion, in this comprehensive study of interac-
tions among established type 1 diabetes susceptibility
genes, we found that the joint effect of HLA and PTPN22
was significantly less than multiplicative in the case-control
material, while a multiplicative model could not be rejected
for HLA-INS, HLA-CTLA, PTPN-INS, INS-CTLA4 and
PTPN-CTLA4. Despite near-multiplicative effects for most
loci, and the fact that groups with very high relative risk of
type 1 diabetes can be identified by testing for multiple
susceptibility genes, only a small proportion of the popu-
lation (and cases with type 1 diabetes) simultaneously carry
HLA and multiple non-HLA susceptibility genotypes.
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